Oxford

Clinical Genomics & Molecular Diagnostics

10:00 – 17:00
Monday 19th November 2018
Oxford Spires Hotel, Abingdon Road, Oxford, OX1 4PS

The ‘Clinical Genomics & Molecular Diagnostics Meeting’ is a medical education meeting in lymphoid malignancies focusing on Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL). The meeting will bring together a notable faculty of oncology experts who will preview the latest advances in research, consider the likely impact on the clinic of tomorrow, and discuss and debate the pertinent issues which are affecting the professional community. The meeting offers you and the audience the opportunity to discuss with peers and experts the latest scientific data likely to shape the treatment paradigms in these respective fields.

 


Chair

Dr Anna SchuhDr Anna Schuh
Associate Professor,
Director of Molecular Diagnostics,
Honorary Consultant Haematologist,
University of Oxford, UK

Programme
The full programme can be viewed HERE


Who should attend?
This meeting is ideal for:

  • Nurses
  • Consultants
  • GPs
  • Pharmacists
  • Researchers and
  • Scientists

and any healthcare professionals who have an interest in the future shape and direction of FL & CLL research and treatment.


CPD
‘Clinical Genomics & Molecular Diagnostics’ (code: 122675) has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 5 category 1 (external) CPD credit(s). Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing.


When & Where
Monday 19th November 2018, 09:30 – 17:00
Oxford Spires Hotel,
Abingdon Rd,
Oxford. OX1 4PS.
Map here


Costs
The meeting costs are underwritten by Gilead Sciences Ltd. and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.